NextFin News - Innovent Biologics (01801.HK) shares surged 6.7% in Hong Kong trading on Friday, March 27, 2026, after the company reported its first-ever annual net profit, marking a definitive end to the "cash-burn" era that has long defined China’s biotechnology sector. The Suzhou-based drugmaker posted a net profit of RMB 813.6 million for the 2025 fiscal year, a dramatic swing from the losses of previous years, as total revenue climbed 38.4% to exceed the RMB 13 billion threshold for the first time.
The milestone is more than just a corporate victory; it serves as a proof of concept for the "dual-driven" strategy championed by the company’s leadership. Product revenue, the engine of this growth, jumped 44.6% to RMB 11.9 billion. This surge was fueled by the continued dominance of its PD-1 inhibitor, Tyvyt (sintilimab), and the rapid market uptake of newer oncology treatments. However, the real catalyst for the stock’s performance on Friday was the burgeoning contribution from its non-oncology portfolio, specifically in the metabolic and cardiovascular space.
Market sentiment was particularly buoyed by the performance of mazdutide, the company’s GLP-1/GCGR dual agonist. As obesity treatments become a global pharmaceutical gold rush, Innovent’s early positioning in the Chinese market has begun to yield tangible financial results. Licensing income also played a critical role, reaching RMB 957.3 million, as the company deepened strategic partnerships with global giants like Eli Lilly. This shift from a pure R&D shop to a commercially viable powerhouse has forced a re-evaluation of the company’s valuation multiples among institutional investors.
Despite the celebratory mood on the trading floor, some analysts remain cautious about the sustainability of this margin expansion. While the company has successfully optimized its selling and distribution expenses—which grew at a slower pace than revenue—the competitive landscape for PD-1 therapies in China remains cutthroat. Price erosion due to the National Reimbursement Drug List (NRDL) negotiations continues to be a persistent headwind for the entire sector. Furthermore, the heavy reliance on a few blockbuster assets means any regulatory or clinical setback in the late-stage pipeline could disproportionately impact future earnings.
The broader context of U.S. President Trump’s trade policies also looms over the sector. While Innovent is primarily focused on the domestic Chinese market, any escalation in biotech-related export controls or investment restrictions could complicate the company’s long-term global aspirations. For now, however, the transition to profitability provides Innovent with a significant capital cushion, allowing it to fund its early-stage "global innovation" pipeline without the immediate need for dilutive equity raises. The market’s 6% vote of confidence suggests that for the first time, investors are valuing Innovent not just on its potential, but on its proven ability to generate cash.
Explore more exclusive insights at nextfin.ai.
